Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment
Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months
Novo Nordisk and Hims bury the hatchet and carve a deal (2 days)
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (8 days)
GLP‑1 drugs associated with lower addiction risk in large study (10 days)
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)
Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.